EverZom Revenue and Competitors
Estimated Revenue & Valuation
- EverZom's estimated annual revenue is currently $2.1M per year.
- EverZom's estimated revenue per employee is $98,000
Employee Data
- EverZom has 21 Employees.
- EverZom grew their employee count by -9% last year.
EverZom's People
Name | Title | Email/Phone |
---|---|---|
1 | Ingénieur recherche/développement | Reveal Email/Phone |
2 | Ingénieur projet, recherche et développement | Reveal Email/Phone |
EverZom Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $14.3M | 102 | 12% | N/A | N/A |
#2 | $6.7M | 53 | -10% | N/A | N/A |
#3 | $17.4M | 124 | -2% | N/A | N/A |
#4 | $4M | 38 | 6% | $15.5M | N/A |
#5 | $18.2M | 130 | -8% | $34.5M | N/A |
#6 | $8.8M | 70 | -18% | N/A | N/A |
#7 | $9.5M | 75 | N/A | N/A | N/A |
#8 | $4.4M | 39 | N/A | N/A | N/A |
#9 | $1.4M | 17 | N/A | N/A | N/A |
#10 | $1M | 12 | N/A | N/A | N/A |
What Is EverZom?
EverZom is a nanomedecine biotech companies developing a GMP compliant extracellular vesicle manufacturing platform based on a unique proprietary technology for pharmaceutical researchers developing breakthrough biotherapies. Extracellular vesicles which encompass exosomes, microvesicles and apoptotic bodies are the tools used by cells to communicate with each others. Extracellular vesicles have reparative and regenerative properties and are seen as an alternative to cell therapies for tissue regeneration. They eliminate many of the risks associated with cell therapies and carry significant benefits that the medical world considers to be game changing. There is a major challenge in the production of extracellular vesicles at commercial scale which is holding back the development of new therapies. EVerZom aims at overcoming this challenge with its breakthrough patented production method. This technology was developped in collaboration with the Laboratory Matières et Systèmes Complexes from the University of Paris and the CNRS. As an exosome CRO, we provide exosome characterization services, exosome quality control and analytics services, isolation, purification services, process development and manufacturing services.
keywords:N/AN/A
Total Funding
21
Number of Employees
$2.1M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EverZom News
Global Exosome Development and Manufacturing Services Market Report 2022-2035 with Executive Insights from EVerZom, Clara Biotech,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.1M | 21 | -12% | N/A |
#2 | $2.1M | 21 | -25% | N/A |
#3 | $2.1M | 21 | -16% | N/A |
#4 | $3M | 21 | N/A | N/A |
#5 | $2.1M | 21 | N/A | N/A |